Supported by an educational grant from Novo Nordisk
A new generation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including an oral formulation, may reshape the care of patients with type 2 diabetes mellitus (T2DM). Two key members of the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines panel, Professor Melanie Davies and Professor Chantel Mathieu, provide updates on the 2018 ADA/EASD treatment guidelines, and present recent clinical trials data—including studies presented at the 2019 annual meeting of the ADA—on long-acting GLP-1 RAs that may change clinical practice. The discussion focuses on comparative data of the spectrum of GLP-1 RAs with regard to efficacy, safety, weight-loss, and impact on patients with and without established cardiovascular disease (CVD).
Primary care (family medicine/internal medicine) MDs, DOs, NPs, PAs, and other providers who care for patients with diabetes.
At the conclusion of this activity, participants should be better able to:
Summarize the ADA/EASD consensus update and its practical impact on clinical decision-making
Outline the role for long-acting GLP-1 RAs in multidimensional care of the patient with T2DM
Apply the principles of shared decision-making in a collaborative model of diabetes care
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Melanie J. Davies, CBE, MB, ChB MD, FRCP, FRCGP Diabetes Research Center, University of Leicester Leicester Diabetes Centre Leicester General Hospital Leicester, England, UK
Dr. Davies receives grants/honoraria from Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Sanofi-Aventis, and Takeda. She is also on the speakers’ bureaus of Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi-Aventis, and Takeda. Additionally, Dr. Davies is a consultant for/or is on the Advisory Boards of Janssen, Lilly, Novo Nordisk, Sanofi-Aventis, and Servier.
Chantal Mathieu, MD, PhD Clinical and Experimental Endocrinology UZ Gasthuisberg, KU Leuven Leuven, Belgium
Dr. Mathieu is a consultant for/is on the Advisory Boards of/is on the Speakers’ Bureaus of Adocia, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dianax, Eli Lilly, GSK, Intrexon, Janssen, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education (HME), or Novo Nordisk. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.